# Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

> **NCT00825812** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 308 (actual)

## Conditions studied

- Anesthesia, General
- Neuromuscular Blockade

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** neostigmine

## Key facts

- **NCT ID:** NCT00825812
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825812, "Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00825812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*